echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Gastroenterology: Engineering FGF-19 similarity Aldafermin treats NSAH Phase II clinical success

    Gastroenterology: Engineering FGF-19 similarity Aldafermin treats NSAH Phase II clinical success

    • Last Update: 2021-01-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Aldafermin (NGM282) is an engineered FGF-19 similar that, in a previously published 12-week study, significantly inhibited bile acid synthesis and reduced liver fibrosis, inflammation, and fatty degeneration.
    researchers recently published the full results of Aldafermin's clinical study on the treatment of non-alcoholic fatty hepatitis (NASH) Phase II.
    The study was conducted in 9 U.S. centers with 78 NASH patients who received a biopsy that confirmed non-alcoholic fatty liver activity scores ≥4, 2 or 3 fibrosis, MRI absolute liver fat content ≥8 percent), and random placebo (n-25) or aldafermin (n-53, 1mg daily) treatment for 24 weeks.
    of the study was 24 weeks, the absolute liver fat content changed compared to the baseline, with secondary endpoints including serological and histological fibrosis and NASH improvement.
    24 weeks, the absolute liver fat content of the aldafermin group was reduced by 7.7 percent compared to the baseline, while the placebo group was reduced by 2.7 percent.
    aldafermin therapy was better than placebos in reducing 7 alpha-hydroxy-4-cholesterol-3-ketones, bile acid, alanine and tyrosine transaminase, and Type III. collagen pre-peptides (Pro-C3).
    38 percent of patients in the aldafermin treatment group had more than 1 level of fibrosis and no NASH symptoms, while only 18 percent in the placebo group.
    of patients with NASH remission and no increase in fibrosis were 24 percent in the aldafermin treatment group and 9 percent in the placebo group.
    patients in the aldafermin treatment group withdrew from the study due to adverse events, and 4% of patients in the placebo group withdrew from the study due to adverse events.
    Phase II study confirmed that aldafermin reduced liver fat content and improved fibrosis in patients with non-alcoholic fatty hepatitis.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.